Sonesitatug Vedotin Demonstrated a Statistically Significant and Highly Clinically Meaningful Improvement in Overall Survival in 2nd and Later-Line CLDN18.2-Positive Advanced Gastric/GEJ Cancers
Phase 3positiveSonesitatug VedotinPositive
AI Analysis
Summary
Sonesitatug vedotin demonstrated statistically significant and clinically meaningful improvement in overall survival in the Phase 3 CLARITY-Gastric01 trial for 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Statistically significant and clinically meaningful improvement in overall survival
Importance:8/10
Sentiment:
0.90
oncologygastric cancerphase 3positive dataantibody-drug conjugate
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on July 27, 2026 11:07 PM